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INTRODUCTION
Cord blood (CB) and autologous mobilized peripheral
blood stem/progenitor cells (PBSC) are used widely as alter-
native sources for hematopoietic cell transplantation grafts
[1–3]. A patient and physician may be faced with a choice
between (allogeneic) CB or (autologous) PBSC as a source
of stem/progenitor cells for a therapeutic transplant. How-
ever, comparative clinical information is still limited on the
long-term clinical engraftment capacity of hematopoietic
cells from these two sources and the clinical information is
not quantitative [2–4]. Large autologous PBSC harvests col-
lected from adult cancer patients on chemotherapy usually
contain large numbers of CD341 cells (,108–109 in a typical
PBSC transplant graft preparation), but the long-term pro-
liferative capacity of the stem/progenitor cells in PBSC col-
lections may be reduced by prior chemotherapy or cytokine
therapy [5–7]. In comparison, CB collections from healthy
newborns contain many fewer total cells and total CD341
cells (,106–107 CD341 cells in a typical CB transplant graft
preparation), but the CB stem/progenitor cells might have
higher proliferative capacity (because younger individuals
may have more potent or earlier stem/progenitor cells, or
CB donors have not received chemotherapy or other treat-
ment or both). Thus far, all available in vitro hematopoietic
assays fail to measure long-term repopulating ability or lym-
phohematopoietic differentiating ability, the most important
characteristics of long-term repopulating cells [8]. The use
of human clinical gene marking trials to determine the con-
tribution of autologous PBSC to long-term engraftment is
technically demanding and not yet quantitative because of
the low efficiency of gene transfer [4]. Recently, sublethally
irradiated nonobese diabetic-scid/scid (NOD/SCID) mice
have been found to support the growth of transplanted
human hematopoietic cells [9]. Using limiting dilution
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PBSC from cancer patients, long-term engrafting cells were approximately eightfold enriched in CB CD341 cells,
and each CB long-term engrafting cell had an ,15-fold higher multilineage proliferative capacity. Thus, the number
and function of transplantable hematopoietic cells were remarkably different between these two sources of
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analysis with the NOD/SCID xenotransplant model, Wang
et al. found that the frequency of engrafting cells at 4–6
weeks after transplantation was 1 in 9.33105 mononuclear
cells in CB grafts and 1 in 63106 mononuclear cells in
PBSC grafts from normal adult donors [10]. We developed a
multiple linear regression model that allows comparisons of
levels of human hematopoietic cell engraftment in
NOD/SCID mice. We found that the short-term (4–8
weeks) engraftment potential per transplanted CD341 cell
was ,50-fold higher for CB than for PBSC from cancer
patients undergoing chemotherapy [11]. Because the long-
term engraftment capacity of hematopoietic grafts carries
important implications for clinical transplant and gene ther-
apy [3,4], the present investigation further characterized the
engraftment kinetics resulting from CD341 cells of these
two sources during the whole lifespan of the murine recipi-
ents. In addition, because the number of active stem cells
also has significant implications for gene therapy [12], we
quantified the frequency of long-term engrafting cells using
a competitive repopulation assay with binomial variance-
covariance modeling [13–15]. Results from the latter assay
allowed the estimation of the average proliferative capacity
of individual long-term engrafting cells.
PATIENTS AND METHODS
Human cells
CB samples from placentas of healthy newborns collect-
ed by Poietic Technologies (Gaithersburg, MD) were pur-
chased. PBSC were obtained as small aliquots from good-
yield (.23106 CD341 cells collected/kg) autologous leuka-
pheresis mobilized blood products from cancer patients
undergoing chemotherapy at the Johns Hopkins Hospital
under an institutional review board-approved protocol. The
PBSC mobilization regimen was cyclophosphamide 
(4 gm/m2) followed by G-CSF (10 mg · kg–1 · day–1 until the
day of the single large-volume leukapheresis [16]. Both CB
and PBSC were thawed using the method of Rubinstein et
al. [17]. Viability was .95% in all samples by trypan blue
exclusion. CD341 cell purification was performed using
immunomagnetic beads, as previously described [18,19].
DESIGN
Eighty nonobese diabetic/LtSz-scid/scid (NOD/SCID)
mice were randomized to receive either CB or autologous
PBSC [20]. A large concurrent control experimental design
with multiple timepoints was chosen instead of several small
sequential experiments. The large sample size and the con-
current controlled nature of this experiment tended to
increase internal validity and protect against random error
and potential bias arising from such factors as day-to-day
experimental error or recipient bias [21]. Cells pooled from
20 CB or four PBSC specimens were used to estimate the
differences in engraftment and stem cell frequencies
between these two types of clinically relevant grafts rather
than variability among individual CB or PBSC samples.
Pooling the cells before transplantation is particularly
important in this kinetic study, since it prevents significant
influence from peculiarities in any sample on the time-
dependent engraftment variables (see “Statistical analysis”).
TRANSPLANTATION OF HUMAN CELLS
Human CD341 cells were transplanted by tail vein
injection into sublethally irradiated (350 cGy using a 137Cs
g-irradiator) 6- to 8-week-old NOD/SCID mice. All mice
received human interleukin-3 (IL-3), granulocyte-macro-
phage colony-stimulating factor (GM-CSF), granulocyte
colony-stimulating factor (G-CSF), and stem cell factor
([SCF]10 mg of each/dose; Amgen, Thousand Oaks, CA)
intraperitoneally every Monday, Wednesday, and Friday
post-transplantation, to maximize levels of human cells in
the engrafted human-murine chimeras [11]. Mice were bred
and maintained in pathogen-free conditions as described
[19,20]. Animal experiments were approved by the Animal
Care and Use committee of the Johns Hopkins Medical
Institutions. Mice were killed 2–20 weeks after transplanta-
tion, as specified, for removal of organs. Week 20 after
transplantation was chosen as the latest time point, because
the average lifespan of this mouse strain is only ,8 months
due to its high incidence of thymic lymphomas [20].
Analysis of human cell engraftment
Single-cell suspensions were prepared from removed
spleens. Bone marrow cells were obtained by flushing both
the removed femurs and tibiae from each animal. Cells were
counted using a Coulter Z1 cell counter (coefficient of vari-
ance ,3%; Coulter, Miami, FL). Because these four bones
contain ,25% of the total marrow volume of a mouse [22],
the total number of marrow cells was estimated by multiply-
ing the number of cells obtained by 4. Human cells were
enumerated and cell lineages determined by 3-color flow
cytometry (fluorescence-activated cell sorter [FACS]; Becton
Dickinson, San Jose, CA) using murine monoclonal anti-
human leukocyte antibodies as described previously (Fig. 1)
[18,19]. Estimates of measurement error for the percentage
of human CD451 cells in the chimeras were obtained from
repeated, independent sampling of a 40:60 and a 1.5:98.5
mixture of human to murine leukocytes. These error esti-
mates were used for adjusting variances, as described in Table 1.
Colony-forming assays were performed using described
methods that were shown to be selective for the growth of
human colonies in a murine cell background [19,23].
Statistical analysis
The number of primitive cells that contributed to long-
term engraftment was estimated using the binomial vari-
ance-covariance model developed by Stone and Harrison et
al. [13–15]. This model does not quantify those quiescent
hematopoietic cells that may be present but do not con-
tribute to engraftment. Therefore, we adopted the term
“contributory cells” used by Stone and Harrison et al. and
called these cells contributory engrafting cells (CECs). In
this study, instead of competition between murine cells of
different genotypes, we measured the competition between
human vs. murine hematopoietic cells. For cohort of recipi-
ents of identical aliquots of the same CB or PBSC CD341
cell pool, the percentage of human CD451 (murine CD45–)
cells in the marrow or spleen was measured by flow cytome-
try. Statistically, the higher the number of stem cells in the
aliquots, the lower the variability in the percentage of
human CD451 cells in the chimeras (e.g., the sampling vari-
ability of 50 stem cells is lower than that of five stem cells).
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Separate calculations were made for the CB and PBSC
groups and for the marrows and spleens of the chimeras.
For example, for the marrows of the recipients of PBSC, we
calculated: mean 5 the average % of human CD451 cells in
their marrows; SD 5 the standard deviation of the % of
human CD451 cells. The estimate of 1/p m is then given by
the formula: (mean)(100–mean)/SD2, where p m is the proba-
bility that two cells drawn independently at random from
the marrow of a recipient were produced by the same CEC.
Using this binomial formula avoids the unverified assump-
tion that the proliferative capacity of each murine CEC is
equivalent to that of each human CEC [13,14].
An alternative approach to the estimation of the number
of CEC contributing to two cell compartments (e.g., mar-
row and spleen) is based on the covariance of the propor-
tions of human CD451 cells in the two compartments of
each recipient [13,14]. For this, the analogue of p m would be
p ms, which is the probability that a randomly sampled cell
from the marrow and a randomly sampled cell from the
spleen descended from the same CEC.
An advantage of using covariance-based, rather than
variance-based, estimates is that there is no bias (arising from
experimental error or any other source of error that is uncor-
related in the two compartments) to be removed. However,
its validity in this context rests on the assumption that the
development of the CD451 cells in the two compartments is
highly correlated (i.e., higher engraftment in the spleen of a
chimera accompanied higher engraftment in its marrow)
[14]. In human/murine xenotransplants, high engraftment in
marrow was associated with an enlarged spleen attributable
to compensatory murine hematopoiesis [23]. Thus, the per-
centage of human cells in the spleen of a highly engrafted
animal could occasionally be decreased by the increase in
number of murine cells in the denominator. This paradox
may decrease the covariance of the proportions of human
cells in the marrows and spleens (see footnote in Table 1).
RESULTS
Short- and long-term engraftment potential 
of CB vs. PBSC
For the first cohort, 40 mice were each transplanted
intravenously with 0.5 million CD341 CB cells (96%
CD341) from a pool of CB cells assembled from 20 CB
specimens. In the second cohort, another 40 mice were each
transplanted with 3 million CD341 cells from a pool of
PBSC. CD341 cells were purified from a pool of PBSC
obtained from four patients with Ewing’s sarcoma or breast
cancer who had received 3–6 cycles of chemotherapy before
leukapheresis. All the PBSC were obtained from individual
collections, which contained .23106 CD341 cells/kg. The
pooled PBSC preparation of CD341 cells was 96% CD341.
Chimeras were killed at 2, 4, 8, 14, or 20 weeks after trans-
plantation for detailed immunophenotypic analysis of
human cells in their marrows and spleens. As shown in Fig-
ure 2, high levels of human cell engraftment were found in
the marrows and spleens of the chimeras of both cohorts in
the first 4 weeks after transplantation. For the cohort that
received PBSC, however, the levels of engraftment in both
marrows and spleens dropped significantly by 8 weeks after
transplantation and remained lower at all later time points.
In contrast, the levels of engraftment were maintained at
relatively high levels for the chimeras that received CD341
CB cells, even though sixfold fewer CD341 cells had been
transplanted. These results were consistently observed at
multiple long-term time points ($8 weeks).
Kinetics of different populations of human 
hematopoietic cells
Comparisons were then made between the chimeras
that received CD341 cells from CB vs. PBSC in engraft-
Figure 1. Flow cytometric analysis
A flow cytometric profile of marrow cells from a chimera 20 weeks after trans-
plantation with 0.5 million CD341 CB cells. (A) The percentage of human
cells in the marrow were enumerated by flow cytometry as cells labeled with
the anti-human CD45 phycoerythrin-Cy5 monoclonal antibody (mAb), but
not anti-mouse CD45 FITC mAb. (B) Immunophenotypes of the cells in gate
R1 were then determined by expression of mAb-defined human leukocyte 
differentiation antigens as indicated. Isotype control mAb were used to assess
non-specific staining.
A
B
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ment kinetics of various subsets of human hematopoietic
cells. As shown in Figure 3A, at 2–8 weeks after transplanta-
tion, large numbers of human CD191 (pan-) B lymphoid
cells were found in the marrows and spleens of the
chimeras, which had received either CB or PBSC. Many
human CD201 (phenotypically mature) B lymphoid cells
were found in their marrows at 4–8 weeks after transplant,
as well as in their spleens at 8 weeks after transplant. At
14–20 weeks after transplant however, the numbers of
CD191 and CD201 human cells had decreased exponential-
ly in the marrows and spleens of the chimeras that had
received CD341 PBSC. This is in contrast to the chimeras
that had received CD341 CB cells in which high (stable)
numbers of CD191 and CD201 B lymphoid cells were
found at late as well as earlier time points.
Throughout the 20 weeks of study, large numbers of
CD131 and CD151 human myeloid cells were found in the
marrows and spleens of the chimeras that had received
CD341 CB cells (Fig. 3B). On the other hand, the number
of CD131 and CD151 myeloid cells in the spleens and
CD151 cells in the marrows of the chimeras that had
received CD341 PBSC decreased exponentially .8 weeks
after transplant. After 8 weeks, the cells found in the mar-
rows of chimeras that had received CD341 PBSC were
mostly CD131CD152 cells.
The numbers of stem/progenitor cells in these chimeras
were also compared. As shown in Fig. 4, the numbers of
CD341 cells in the marrows of the chimeras that had
received CD341 CB were persistently higher than the initial
inoculum (i.e., 0.5 million). In contrast, for the chimeras
that received (3 million) CD341 PBSC, the number of
CD341 cells in the marrows decreased exponentially in the
first 8 weeks after transplantation, then stayed at a relatively
low (,1% of the cell number transplanted), steady level
through week 20. Similar kinetics were observed for the
total number of colony-forming cells (CFCs) in the mar-
rows of the chimeras as measured by colony-forming assays.
Although the numbers of CFCs were similar between the
two cohorts at 2 weeks after transplantation, this number
decreased continuously thereafter for the chimeras that had
received CD341 PBSC (Fig. 4). The distribution of the sub-
classes of CFCs also differed. In the first 4 weeks after trans-
plantation, most of the CFCs in the chimeras that received
CD341 PBSC were CFU-E, whereas most of the CFCs in
chimeras that received CD341 CB were earlier progenitors
(e.g., CFU-GEMM; Table 2). Thereafter, all types of pro-
genitors were present in the chimeras that received CD341
Figure 2. Short- and long-term engraftment potential of CB vs.
PBSC
Forty mice were each transplanted with 0.5 million cells from the pooled CB
CD341 cells. Another 40 mice were each transplanted with 3 million cells
from the pooled CD341 cells from PBSC harvested from cancer patients.
Upper panels show the percentages of human CD451 cells found in the mar-
rows and spleens of the chimeras 2–20 weeks after transplantation with CB
(m) or PBSC (x). Lower panels show the corresponding total numbers of
human CD451 cells per chimera. Values shown are the mean 6 SEM of
results of individually assessed animals (24 mice per cohort at 8 weeks, four
mice per cohort at each other time point).
Table 1. Number and proliferative capacity of long-term CECs
Marrows Spleens Marrows and spleens
Cell CD341 % human PC of % human PC of
source cellsa Mean SD 1/pm CECs
b CECs (106) Mean SD 1/ps CECs
b CECs (106) COVA 1/pms CECs
b
CB 0.5 38.6 14.1 12.2 4 20 37.3 13.1 13.9 4 9.4 46.4 50.8 ND
(n=24)
PBSC 3 2.0 1.6 76.8 0.5 1.2 2.0 1.7 68.1 0.5 0.8 2.2 89 0.6
(n=24)
aNumber CD341 cells transplanted per mouse (106).
bPer 106 CD341 cells.
CECs, contributory engrafting cells; CFC, colony-forming cell; COVA, covariance; n, number of mice; ND, not determined since the correlation coefficient was
,0.75 [8]; PC, proliferative capacity; SD, standard deviation about the mean.
Controls for experimental error in the measurement of the percentage of human CD451 cells in murine background were determined by repeated, 
independent sampling from an intended 40:60 or 1.5:98.5 mixture of human:murine leukocytes. The results by flow cytometry were 37.8 – 2.1% and 
1.2 – 0.1%, respectively. 1/pm and 1/ps were estimated as p(100 – p)/([SD]2 – [SD controls]2), where 1/pm or 1/ps is the probability that two cells from
the marrow or spleen, respectively, of an individual chimera, drawn independently at random were produced by the same long-term CECs. This value was
used to derive the number of CECs per 106 CD341 cells (APPENDIX), together with the proliferative capacity of each CEC. 1/pms is the probability that a
cell drawn randomly from the marrow and another cell drawn randomly and independently from the spleen of an individual chimera were produced by the
same long-term CEC. Calculation using this covariance method gave very similar results for the number of long-term CFCs in the PBSC.
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CB, except for CFU-E. In contrast, the only type of pro-
genitor detected in chimeras .14 weeks after transplanta-
tion with CD341 PBSC was CFU-GM. Note that, as
described earlier, complete human erythropoietic develop-
ment was poorly supported in these mice [9,19].
Frequency of long-term CECs in CB vs. PBSC
After the first phase of engraftment [24], 20 mice (in
addition to the four mice killed at 8 weeks) from each cohort
were killed at 8–10 weeks after transplant to quantify the
number of long-term CECs by using the binomial competi-
tive repopulation model. The estimated frequencies of long-
term CECs were 1 in 2.53105 CD341 CB cells and 1 in
23106 CD341 PBSC, an eightfold difference (Table 1 and
APPENDIX). These estimates were very similar for marrows
and spleens. Calculations using the covariance method also
gave a similar result for the number of CECs in PBSC. The
frequency of long-term CECs in CD341 CB was not esti-
mated using the covariance model because the percentage of
human CD451 cells in the marrows and spleens was not
highly correlated (r , 0.75), and the proliferative capacity of
CB CECs could not be assumed to be similar to that of
murine CECs (Table 1 and APPENDIX) [15].
Proliferative capacity of individual CECs
Each CB long-term CEC resulted in ,20 million
human CD451 cells in the chimeras’ marrows and ,9 mil-
lion in their spleens at 8–10 weeks after transplant. In con-
trast, each PBSC long-term CEC at 8–10 weeks resulted in
only ,1.2 and ,0.8 million CD451 human cells in the
chimeras’ marrows and spleens, respectively. Thus, the pro-
liferative capacity was ,12- to 15-fold higher for each CB
long-term CEC over each PBSC long-term CEC. Taken
together with the difference in the frequency of long-term
Figure 3. Engraftment kinetics of different populations of hematopoietic cells
A and B show the numbers of human cells (expressing the human leukocyte differentiation antigens indicated) found in the marrows (left panels) or spleens (right
panels) of the chimeras shown in Figure 2. Values shown are the mean 6 SEM of results of individually assessed animals (•, CB; x, PBSC).
Figure 4. Numbers of CD341 cells and CFCs in the bone marrow of the chimeras
Values shown are the mean – SEM of results of individually assessed animals shown in Figure 2 (m, CB; x, PBSC). The dotted line shows the number of CD341
cells present in the original inocula.
A B
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CEC, CD341 cells from CB had an ,100-fold higher
engraftment potential over CD341 cells from PBSC.
DISCUSSION
Both CB and autologous PBSC are now used widely for
clinical transplantation. In some patients, there is a need to
choose between a transplant graft of autologous PBSC or
allogeneic CB. Our results indicate a remarkable difference
in the number and function of transplantable hematopoietic
cells in the CD341 cells from these two sources. In this
study, the engraftment kinetics of CB vs. autologous PBSC
from cancer patients undergoing chemotherapy were remi-
niscent of the two phases of engraftment following murine
syngeneic bone marrow transplantation [24]. Jones et al.
suggested that the first unsustained short-term phase was
produced by committed progenitors, whereas the second
sustained long-term phase was due to pluripotent stem cells.
When compared with CD341 cells from autologous PBSC
on a per-cell basis, CD341 cells from CB had an ,10-fold
higher short-term (2–4 weeks) engraftment potential. Thus,
transplantation of a PBSC graft containing ,10-fold more
CD341 cells (vs. a CB graft) would result in similar levels of
B lymphoid, myeloid, and erythroid engraftment in
chimeras assessed at 2–4 weeks after transplant. This predic-
tion was based on our prior report that there was a linear
dose-response relationship between the number of human
CD341 cells transplanted and the number of human cells
engrafted in the chimeras [11]. If these results are extrapo-
lated to human hematopoietic cell transplantation and
adjusted for the usual ,50-fold higher numbers of CD341
cells harvested in an autologous PBSC graft vs. a CB graft,
our results indicate that autologous CD341 PBSC may be a
richer source of hematopoietic cells for rapid erythroid,
granulo-monocytic, and B lymphoid reconstitution. This is
in agreement with the clinical observation that autologous
PBSC provided more rapid trilineage (erythroid, granulo-
moncytic, and lymphoid) blood cell count recovery in
patients than did CB [1,2].
In our experiments, 32 chimeras of each group (CB or
PBSC) were killed .8 weeks after transplantation. When
compared with CD341 cells from CB on a per-cell basis,
CD341 cells from autologous PBSC had a much lower long-
term (.8 weeks, second phase) engraftment potential. The
high level of engraftment in the first 4 weeks for the cohort
that received autologous PBSC proved that CD341 cells
homed and proliferated in the NOD/SCID bone marrow
microenvironment. Nevertheless, the engraftment was not
sustained; only very low levels of human CD191 and CD201
B lymphoid cells, as well as CD131 and CD151 myeloid cells,
were detected in the marrows and spleens of the 32 chimeras
that had received CD341 PBSC .8 weeks after transplant.
Moreover, .1% of the original transplanted number of
CD341 cells from PBSC were found in the marrows .8
weeks after transplant. The number of CFCs, as assayed by
colony-forming assays, in the marrows also decreased expo-
nentially after 2 weeks. Overall, we found that CB CD341
cells had an ,120-fold higher long-term engraftment poten-
tial on a per-cell basis when compared with PBSC CD341
cells. Even after adjustment for the usual ,50-fold higher
number of CD341 cells in a PBSC (compared with a CB)
transplant graft, CB is a more potent source for long-term
lympho-hematopoietic engraftment in this chimera model.
The higher long-term engraftment potential of CB vs.
PBSC could be due to a higher frequency of long-term
CECs or a higher proliferative capacity for each CEC or
both. This was tested using the competitive repopulation
analysis with binomial variance-covariance modeling using
data from the 48 chimeras that were killed 8–10 weeks after
transplant. We found that long-term CECs were not only
enriched (approximately eightfold) in the CD341 fraction of
CB (compared with PBSC), but also had an ,15-fold higher
proliferative capacity per CEC. The low frequency of long-
term CECs in CD341 PBSC suggested that only a very tiny
fraction of the cyclophosphamide plus G-CSF–mobilized
CD341 PBSC contributed to long-term engraftment. More-
over, the proliferative capacity of each CEC was reduced,
which could be explained by age effect (i.e., adults donated
PBSC) [5,6], difference in progenitor cell cyling activity
[25,26], or prior chemotherapy or cytokine therapy (given to
the patients whose PBSC were tested) [7]. Long-term
engraftment may not be a significant concern in the use of
hematopoietic cells for autologous hematopoietic rescue
after high-dose therapy for solid cancers, since eventual
resurgence of non-transplanted endogenous stem cells is
possible after non-myeloablative chemotherapy. In contrast,
these findings may have important implications for the use of
autologous PBSC rescue for myeloablative therapies for
hematologic malignancies (e.g., chronic myeloid leukemia or
acute myeloid leukemia) [27,28], as well as for gene therapy
with autologous PBSC [3,29]. First, these clinical transplan-
tation situations require sustained, long-term immunohe-
matopoietic reconstitution (or durable high-level gene
expression). Second, low-level long-term engraftment may
provide a competitive advantage to abnormal clones result-
ing from prior exposure to chemotherapy. This biology may
contribute to the unexpectedly high incidence of myelodys-
plastic syndrome or late autograft failure observed in non-
Hodgkin’s lymphoma patients, despite large numbers of
CFU-GM in the autologous PBSC grafts [30–32]. Without
transplantation, these patients have been considered to be at
minimal risk for the development of myelodysplastic syn-
drome or marrow failure [32]. In this study, CD341 cells
from CB had a higher frequency of long-term CECs and a
higher proliferative capacity of each long-term CEC than
Table 2. Distribution of different subclasses of CFCs after transplantation
Weeks after CB PBSC
transplantion CFU-E:BFU-E:GM:GEMMa CFU-E:BFU-E:GM:GEMM
2 18:34:25:23 41:13:19:27
4 1:5:21:73 62:9:13:16
8 6:48:58:17 0:62:38:0
14 0:73:19:8 0:0:100:0
20 0:58:27:15 0:0:100:0
aThe relative numbers of colony-forming units-erythroid (CFU-E), burst-
forming units-erythroid (BFU-E), and granulocyte-macrophage (GM) and
multilineage (GEMM) CFCs are shown as a proportion of the total human
CFC population detected at each time point. The total number of human
CFCs is shown graphically in Figure 4.
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CD341 cells from PBSC. This extends the prior in vitro evi-
dence that CB may be a preferred alternative clinical source
of hematopoietic cells for long-term reconstitution, ex vivo
expansion, and gene therapy [1].
This report confirms that only a very small number
(,0.5–4 per 106 CD341 cells) of human hematopoietic cells
contribute to long-term engraftment (observed in our 48
chimeras) at a given time, as shown in murine or feline
hematopoiesis [12,33]. This may explain the wide variation
observed over time (,0.001–0.03%; i.e., .1.5 log) in the
frequency of vector DNA-positive peripheral blood granu-
locytes after autologous transplants of CB CD341 cells that
were transduced with an ADA-containing retrovirus in the
setting of low transduction efficiency [34,35]. The observed
frequency of transduced progeny approximates a binomial
distribution with a mean equal to overall transduction effi-
ciency and a variance inversely proportional to the number
of CECs. Thus, even if the overall transduction efficiency
can be increased in the future to as high as ,10% (e.g., by
myeloablation and increased gene transfer efficiency) [34]
for some white cell or megakaryocytic disorders (e.g., chron-
ic granulomatous disease and Glanzmann’s thrombasthenia)
[28,36], life-threatening infection or bleeding may remain a
real danger during the time period when the observed fre-
quency of transduced cells is low.
In conclusion, CD341 cells from CB grafts collected
from healthy newborns provided sustained long-term multi-
lineage engraftment of immunodeficient mice, whereas
CD341 cells from autologous PBSC grafts collected from
cancer patients undergoing chemotherapy provided early
multilineage engraftment that was not well sustained. Only
a small number of CECs accounted for the majority of the
mature hematopoietic cells. In comparison to CD341 cells
from autologous PBSC, long-term CECs were enriched in
the CD341 fraction of CB, and each long-term CB CEC
had a higher inherent multilineage proliferative capacity.
These findings may be important in the development of
strategies for clinical hematopoietic cell therapy and
hematopoietic stem cell biology in general.
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APPENDIX
Let Ncb 5 number of CECs in the CB graft
Npbsc 5 number of CECs in the PBSC graft
Nscid 5 number of CECs in a NOD/SCID host
Ci-pbsc 5 number of CD451 marrow cells derived from the ith
CEC in the PBSC graft
Ci-scid 5 number of CD451 marrow cells derived from the ith CEC of
the host
Ccb 5 average number of CD451 marrow cells produced by each
CB CEC
Cpbsc 5 average number of CD451 marrow cells produced by each
PBSC CEC
Cscid 5 average number of CD451 marrow cells produced by
each murine CEC
Ctotal 5 total number of CD451 (human 1 murine) marrow cells in
each chimera
Assume that all CECs of the same type contribute
equally to the CD451 cells that were sampled, for the mar-
rows of the chimeras that received PBSC.
where 1.83106 was the average total number of human
CD451 cells in the marrow of a chimera (i.e., Cpbsc 3
Npbsc), 89.43106 was the average total number of murine
CD451 marrow cells (i.e., Cscid 3 Nscid), and 91.23106
was the average total number of CD451 (human 1
murine) marrow cells.
Assuming Cpbsc < Cscid, from equation (1.1), Cpbsc <
Cscid < 1.23106.
Then, Nscid < 74.5 and Npbsc < 1.5 (i.e., 0.5 CECs in
106 CD34 PBSC).
The Npbsc estimated by this variance method approxi-
mates very well that estimated using the covariance method
(Npbsc 5 1.8) as shown in Table 1, assuming that Cpbsc <
Cscid.
If the assumption above is incorrect and if Cpbsc .
Cscid, then Npbsc will be ,1. This is impossible since at
least 1 CEC is necessary to produce the human CD451
cells detected. If Cpbsc , Cscid, then 1.8 3 Cpbsc will be
,89.4 3 Cscid. Then, equation (1.1) will also estimate
Cscid < 1.23106 and Cpbsc < 1.23106.
Similarly, for marrows of the chimeras that received CB:
where 39.33106 was the average total number of human
CD451cells in the marrow of a chimera, 62.53106 was the
average total number of murine CD451marrow cells, and
101.63106 was the average total number of CD451 (human
1 murine) marrow cells.
Because Ccb is possibly greater than Cpbsc, whereas
Cscid should be relatively constant in mice with the same
genetic background, we use the Cscid estimated above (i.e.,
Cscid 5 1.23106) to calcuate Ccb. From equation (1.2),
Ccb 5 19.6. Ncb was therefore <2.0 (i.e., 4 CECs in 106
CD341 CB cells), and Nscid < 52.
The same methods were also used to estimate the
number of CECs from the data of the spleens.
Npbsc
S
i=1
Ci-pbsc Ci-pbsc – 1
Ctotal Ctotal – 1
Ncid
S
i=1
Ci-scid Ci-scid – 1
Ctotal Ctotal – 1
pm 5 3 1 3
(1.1)
(1.2)
< 1(Cpbsc)
2
3 Npbsc
(Ctotal)2
(Cscid)2 3 Nscid
(Ctotal)2
[ 5
1
76.8
1.8 3 106 3 Cpbsc 1 89.4 3 106 3 Cscid
(91.2 3 106 )2
=1
12.2
39.3 3 106 3 Ccb + 62.5 3 106 3 Cscid
(101.6 3 106 )2
g76
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